Evidence map›Paper›PMID 42358828›Full record

ArticleOncology research2026

Progression-Free Survival with PARP Inhibitors According to Clinical Risk in Patients with Ovarian Cancer: An Indirect Comparison Using Reconstructed Data.

Lorenzo Gasperoni, Luna Del Bono, Alberto Farolfi, Andrea Messori, Vera Damuzzo

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Lorenzo GasperoniPharmaceutical Department, USL Toscana Centro, Prato, Italy.ORCID https://orcid.org/0000-0001-6427-0809
Luna Del BonoDepartment of Pharmacy, School of Specialization in Hospital Pharmacy, University of Pisa, Pisa, Italy.
Alberto FarolfiMedical Oncology, Breast & GYN Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy.
Andrea MessoriHTA Unit, Regional Health Service, Firenze, Italy.
Vera DamuzzoItalian Society of Clinical Pharmacy and Therapeutics (SIFaCT), Torino, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Ovarian NeoplasmsPoly(ADP-ribose) Polymerase InhibitorsAntineoplastic Combined Chemotherapy ProtocolsBevacizumabFemaleHumansIndazolesMiddle AgedPhthalazinesPiperazinesPiperidinesProgression-Free SurvivalRandomized Controlled Trials as TopicBevacizumabIndazolesniraparibolaparibPhthalazinesPiperazinesPiperidinesPoly(ADP-ribose) Polymerase Inhibitorsadvanced ovarian cancerindirect comparisonIPDfromKMpoly (ADP-ribose) polymerase (PARP) inhibitors

Identifiers

PMID42358828
PMCPMC13292047

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.